Catalyst Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer INGENITO GARY
Catalyst Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144
Catalyst Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Harper Molly
Catalyst Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Daly Richard J
Catalyst Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144
Catalyst Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144
Catalyst Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144
Catalyst Pharmaceuticals | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Catalyst Pharmaceuticals | POS EX: Post-effective amendment filed solely to add exhibits to a registration statement
Catalyst Pharmaceuticals | POS EX: Post-effective amendment filed solely to add exhibits to a registration statement
Catalyst Pharmaceuticals | POS EX: Post-effective amendment filed solely to add exhibits to a registration statement
Catalyst Pharmaceuticals | 8-K: Current report
Catalyst Pharmaceuticals | 8-K: Current report
Catalyst Pharmaceuticals | 10-Q: Quarterly report
Catalyst Pharmaceuticals | 8-K: Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update
Catalyst Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Tierney David S
Catalyst Pharmaceuticals | DEF 14A: Definitive information statements
Catalyst Pharmaceuticals | ARS: Annual Report to Security Holders
Catalyst Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144
Catalyst Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Elsbernd Brian
No Data